Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study.
Cardiovascular Diseases
/ prevention & control
Diabetes Mellitus, Type 2
/ drug therapy
Female
Follow-Up Studies
Heart Disease Risk Factors
Humans
Hypoglycemic Agents
/ pharmacology
Male
Middle Aged
Retrospective Studies
Risk Assessment
Sodium-Glucose Transporter 2 Inhibitors
/ pharmacology
Time Factors
Cardiovascular risk
GLP1 RA
SGLT2i
Type 2 diabetes
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
28
10
2020
revised:
30
12
2020
accepted:
14
01
2021
pubmed:
1
2
2021
medline:
24
4
2021
entrez:
31
1
2021
Statut:
ppublish
Résumé
The aim of this real-world study is to evaluate the effect of glucagon-like peptide1 receptor-agonist (GLP1 RA) and sodium-glucose co-transporter2 inhibitor (SGLT2i) on coronary heart disease (CHD) risk, in patients with type 2 diabetes (T2D) in primary cardiovascular prevention. Data from 312 patients with T2D, without CHD history, starting treatment with GLP1 RA (n = 174) or SGLT2i (n = 138), were retrospectively collected. UKPDS-RE score was used to estimate 10-years risk for CHD before and 6, 12 and 24 months after prescription. The 10-year CHD risk significantly decreased over 24 months in both GLP1 RA and SGLT2i groups (p = 0.037 and p < 0.001, respectively), with 3% and 7% CHD risk reduction already obtained after the first 6 months of GLP1 RA and SGLT2i therapy respectively (p < 0.001 in both groups. Analyses by categories of baseline CHD risk showed significant reductions of CHD risk in the severe risk categories of both groups (p < 0.001). CHD risk reduction obtained with SGLT2i was higher than with GLP1 RA at 6 and 12 months but not at 24 months. This real-world study shows that both GLP1 RA and SGLT2i reduce the 10-year risk for cardiovascular disease in patients with T2D in primary cardiovascular prevention.
Identifiants
pubmed: 33516784
pii: S0168-8227(21)00034-6
doi: 10.1016/j.diabres.2021.108681
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108681Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest C.M. has received speaker fees from AstraZeneca. E.M. reports research support from scientific societies with unrestricted grants from Lilly and from AstraZeneca and personal fees from Merck Serono, AstraZeneca, Abbott, PikDare. G.L. has received honoraria from NovoNordisk, Lilly, AstraZeneca, Sanofi. R.B. has received honoraria or consulting fees from Sanofi, Eli Lilly, Abbott, and AstraZeneca. All other authors declare no conflicts of interests related to this manuscript.